Skip to main content

Better Choice Company to Host Fourth Quarter and Full Year 2024 Financial Results Conference Call on March 27th at 4:30 p.m. ET

TAMPA, Fla., March 07, 2025 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced it will host a conference call and webcast on Thursday, March 27, 2025, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and full year 2024 and provide a business update. Additionally, we have filed a supplemental proxy statement. This filing is part of our ongoing commitment to transparency and shareholder engagement. The supplemental proxy statement can be accessed here. Conference Call and Webcast Information:Event: Fourth Quarter and Full Year 2024 Financial Results Conference CallDate: Thursday, March 27, 2025Time: 4:30 p.m. Eastern TimeLive Call: 1-888-348-8935 or 1-412-317-0454Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1710449&tp_key=75345a2769 For...

Continue reading

Kestra Medical Technologies, Ltd. Announces Closing of Upsized Initial Public Offering

KIRKLAND, Wash., March 07, 2025 (GLOBE NEWSWIRE) — Kestra Medical Technologies, Ltd. (Nasdaq: KMTS) (“Kestra”), a wearable medical device and digital healthcare company, announced today the closing of its upsized initial public offering of 11,882,352 common shares at a public offering price of $17.00 per share. The total gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Kestra, were approximately $202 million. All of the common shares were offered by Kestra. Kestra’s common shares began trading on the Nasdaq Global Select Market on March 6, 2025, under the ticker symbol “KMTS”. BofA Securities, Goldman Sachs & Co. LLC and Piper Sandler acted as lead bookrunners for the offering. Wells Fargo Securities and Stifel acted as bookrunners...

Continue reading

AppTech Payments Corp. Highlights Q4 2024 Financial and Strategic Developments

CARLSBAD, Calif., March 07, 2025 (GLOBE NEWSWIRE) — AppTech Payments Corp. (“AppTech or the “Company”) (NASDAQ: APCX), a fintech company, today shared its Fourth Quarter 2024 financial results. The Company reported an operating loss of $2.1 million ($0.08 per share) versus a $3.4 million loss in the same quarter of 2023 ($0.18 per share). The operating loss for the full year 2024 was $8.8 million ($0.35 per share) versus $18.5 million ($1.01 per share) in 2023. CEO Thomas DeRosa noted that AppTech underwent significant organizational changes in the fourth quarter when a new investor group committed $5 million to improve the Company’s operations; established voting control of the Board of Directors and replaced certain key executives including the CEO and CFO. New CFO Felipe Corrado stated “We are encouraged by the organizational...

Continue reading

Brag House Holdings, Inc. Announces Closing of Initial Public Offering

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) — Brag House Holdings, Inc. (“Brag House” or the “Company”), a premier media technology platform designed for casual college gamers and brands seeking to connect with the Gen Z demographic, today announced the closing of its initial public offering (the “Offering”) of 1,475,000 shares of its common stock at a public offering price of US$4.00 per share. Kingswood Capital Partners, LLC is acting as the Sole Bookrunning Manager and WestPark Capital Inc. is acting as an underwriter. Lucosky Brookman LLP is acting as U.S. securities counsel to the Company, and Dickinson Wright LLP is acting as U.S. securities counsel to the underwriters in connection for the Offering. A registration statement on Form S-1 (File No. 333-280282) relating to the Offering was filed...

Continue reading

Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market

ROCHESTER, N.Y., March 07, 2025 (GLOBE NEWSWIRE) — Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announced that it has notified the Nasdaq Stock Market (“Nasdaq”) of its decision to delist the Company’s shares of common stock, par value $0.0001 per share (the “Common Stock”), from Nasdaq. Trading in the Common Stock on Nasdaq has been suspended since December 18, 2024. Vaccinex intends to file a Form 25 with the Securities and Exchange Commission on or about March 17, 2025 to remove its Common Stock from listing on Nasdaq. The Company’s decision to delist follows its receipt of notice dated December 16, 2024, that the...

Continue reading

Orezone Gold Files Final Short Form Prospectus in Connection With C$35 Million Bought Deal

Final Short Form Prospectus is accessible on SEDAR+ NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) — Orezone Gold Corporation (TSX: ORE, OTCQX: ORZCF) (the “Company” or “Orezone”) is pleased to announce that, further to its press release dated February 23, 2025 in respect of its bought deal offering of common shares of the Company (the “Common Shares”), it has filed a final short form prospectus dated March 7, 2025 (the “Final Prospectus”) with the securities commissions in all provinces of Canada, except Quebec, and has obtained a receipt therefor. The Final Prospectus qualifies the distribution of 42,683,000 Common Shares at a price of C$0.82 per Common Share (the “Offering Price”) for aggregate gross proceeds of C$35,000,060...

Continue reading

Methanex Releases 2024 Sustainability Report

VANCOUVER, British Columbia, March 07, 2025 (GLOBE NEWSWIRE) — Methanex Corporation (TSX:MX) (Nasdaq:MEOH) released its 2024 Sustainability Report today to share its progress on the sustainability topics that are most material to the company and its stakeholders. “I am proud of our global team’s commitment to safety and Responsible Care® and our best-ever safety performance achievement in 2024. Our safety performance puts us in the top ten per cent for safety performance among the American Chemistry Council’s Responsible Care members.1 The Sustainability Report outlines Methanex’s 2024 activities, including how we protect and develop our people, minimize our impact on the environment and contribute to our communities.” said Rich Sumner, President and CEO of Methanex. “I am pleased to report on our progress towards fulfilling our...

Continue reading

Grupo Aeroportuario del Pacifico, S.A.B. de C.V. General Ordinary Shareholders’ Meeting

GUADALAJARA, Mexico, March 07, 2025 (GLOBE NEWSWIRE) — Grupo Aeroportuario del Pacífico, S.A.B. de C.V., (NYSE: PAC; BMV: GAP) (“the Company” or “GAP”) announced the following: Pursuant to a resolution adopted by our board of directors on February 24, 2025, and in accordance with Articles 180, 181, 182 and other applicable articles of the Mexican General Corporate Law and Article 35 of the Company’s by-laws, Grupo Aeroportuario del Pacífico, S.A.B. de C.V. invites its shareholders to the General Ordinary Shareholders’ Meeting on April 24, 2025 at 12:00 p.m. in Ballroom 3, 3rd floor of the Hilton Midtown Hotel, located at Av. López Mateos 2405-300, Col. Italia Providencia, Guadalajara, Jalisco, Mexico, to discuss the following: ANNUAL GENERAL ORDINARY SHAREHOLDERS’ MEETINGAGENDA I. In compliance with Article 28, Section IV of the...

Continue reading

Blueberries Medical Announces C$1 Million Non-Brokered Private Placement

TORONTO, March 07, 2025 (GLOBE NEWSWIRE) — Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or “Blueberries“), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce a non-brokered private placement consisting of the sale of 96,064,935 common shares (“Common Shares”) at a price of C$0.011 per Common Share for aggregate gross proceeds of approximately C$1.05 million (or approximately US$740,000) (the “Offering”). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes. The Offering is expected to close on or about March 25, 2024. It is expected that the Offering will be led by Terraflos Inc. (“Terraflos”), a cannabis company with operations throughout...

Continue reading

S&P Global Ratings affirms Iceland at ‘A+/A-1’, Outlook Stable

S&P Global Ratings has affirmed ‘A+/A-1’ long- and short-term foreign and local currency sovereign credit ratings on Iceland. The outlook is stable. S&P´s ratings on Iceland reflect the country’s very high GDP per capita and strong growth track record, which has been higher than most sovereigns S&P rates in Western Europe, as well as Iceland’s robust institutional framework and sound economic and fiscal policies. The ratings remain constrained by the volatile nature of Iceland’s small, open economy, which, in S&P’s view, is vulnerable to natural events, including volcanic activity, as well as adverse external developments outside of its control, such as geopolitical risks, trade and tariff tensions, and fluctuating terms-of-trade. The small size of Iceland’s economy also somewhat limits...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.